The Pharmacoeconomics of Alternatives to Allogeneic Blood Transfusion

Abstract

The Pharmacoeconomics of Alternatives to Allogeneic Blood TransfusionTransfusion Alternatives in Transfusion Medicine VOLUME 6 NUMBER 1 MARCH 2004( Pa ge 29 )The Pharmacoeconomics of Alternatives to Allogeneic Blood Transfusion MARINUS VAN HULST et al.

Using pharmacoeconomics for policy making: is rational decision making enhanced by applying thresholds for cost-effectiveness?

“…Empirical observations do not appear to confirm the existence of a single value for a maximum price per QALY. Consider the huge differences in costs per QALY of interventions that have been implemented in the field of blood safety -with cost-effectiveness ratios of often several million dollars per QALY -versus primary prevention of cardiovascular disease with statins [13,19]. An explanation for these high ratios in blood safety could be that the implementation of interventions in the past was either not based on economic considerations or on a decision rule based on the WTP per statistical life saved.…”

Health economics of blood transfusion safety – focus on sub-Saharan Africa

“…The methodology of cost-effectiveness analysis and health economics has been discussed in detail in recent review papers [23][24][25][26]. The main study types used in economic evaluation are cost-effectiveness (CEA) and cost-utility analysis (CUA) in which the incremental net costs of a programme are related to the incremental health benefits.…”